{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:29:07Z","timestamp":1794814147378,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cpcardiol.2026.103401","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:18:47Z","timestamp":1784387927000},"page":"103401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-1121","authenticated-orcid":false,"given":"Hilda Elizabeth","family":"Mac\u00edas-Cervantes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Guardado-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Jonathan","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n Ram\u00f3n","family":"Bautista-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hern\u00e1ndez-Tizapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Carrillo-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Fern\u00e1ndez-Y\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-3666","authenticated-orcid":false,"given":"Luis Ricardo","family":"Hinojosa-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Alfredo","family":"Bernal-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Eduardo","family":"C\u00e1rdenas-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Israel","family":"Nava-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Carlos","family":"Caporal-Trejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Emigdio-Loeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Alicia","family":"Hern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciste Habacuc","family":"Mac\u00edas-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2026.103401_bib0001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41572-019-0090-3","article-title":"ST-segment elevation myocardial infarction","volume":"5","author":"Vogel","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013542","article-title":"Trends in acute myocardial infarction by race and ethnicity","volume":"9","author":"Chi","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4239\/wjd.v7.i18.449","article-title":"Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: evidence on health outcomes and anti-diabetic treatment in United States adults","volume":"7","author":"Liu","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/653789","article-title":"Impact of diabetes on cardiovascular disease: an update","volume":"2013","author":"Matheus","year":"2013","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0007","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.numecd.2010.01.008","article-title":"Cardiovascular risk in women with diabetes","volume":"20","author":"Rivellese","year":"2010","journal-title":"Nutr Metab Cardiovasc Res"},{"issue":"381","key":"10.1016\/j.cpcardiol.2026.103401_bib0008","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"For the DAPA-HF trial committes and investigatoris","volume":"38121","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0009","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"For the EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"For the EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Filippatos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0011","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction","volume":"79","author":"Udell","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0013","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.gheart.2018.08.004","volume":"13","author":"Thygesen","year":"2018","journal-title":"Glob Heart"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0016","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0017","unstructured":"Clinical Trial Randomization Tool.\" The National Cancer Institute's Division of Cancer Prevention, https:\/\/ctrandomization.cancer.gov. Accessed January 22, 2021."},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0018","first-page":"e4","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization","volume":"145","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0019","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"Standardized data collection for cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0021","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American College of Cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0022","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0023","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ehf2.13144","article-title":"Heart falure after myocardial infarction: incidence and predictors","volume":"8","author":"Jen\u010da","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0024","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC National cardiac societies; ESC scientific document group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0025","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2016.05.003","article-title":"The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: findings from the acute coronary treatment and intervention outcomes network (ACTION) Registry-get with the guidelines (GWTG) Medicare-linked database","volume":"178","author":"Sutton","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0027","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12872-021-02250-9","article-title":"Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study","volume":"21","author":"Gamaza-Chuli\u00e1n","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200076","article-title":"SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease","volume":"13","author":"Vroegindewey","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0029","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0140-6736(19)31997-X","article-title":"SYNTAX Extended Survival Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial","volume":"394","author":"Thuijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.hrtlng.2008.04.002","article-title":"Quality of life in patients with heart failure: ask the patients","volume":"38","author":"Heo","year":"2009","journal-title":"Heart Lung"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0031","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/eurjpc\/zwae112","article-title":"I don't wanna live forever\" - importance of quality of life in heart failure patients","volume":"31","author":"Schmid","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0032","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","article-title":"Cardiogenic shock: current concepts and improving outcomes","volume":"117","author":"Reynolds","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0033","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0034","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2020.04.004","article-title":"In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg\/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events","volume":"225","author":"White","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0037","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0038","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0039","first-page":"15","article-title":"SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"J Am Coll Cardiol Basic Transl Sci"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors- perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0041","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0042","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jchf.2017.09.015","article-title":"Post-myocardial infarction heart failure","volume":"6","author":"Bahit","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0043","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.hfc.2022.03.003","article-title":"SGLT2 Inhibitors in heart failure: early initiation to achieve rapid clinical benefits","volume":"18","author":"Dixit","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0044","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103401_bib0036","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.arcmed.2019.01.005","article-title":"STEMI and NSTEMI: real-world study in Mexico (RENASCA)","volume":"49","author":"Borrayo-S\u00e1nchez","year":"2018","journal-title":"Archives of Medical Research"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062600143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062600143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:14:33Z","timestamp":1787318073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014628062600143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S014628062600143X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103401","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103401"}}